Researchers pioneer use of new method to treat life-threatening heart arrhythmias in dogs
(Morris Animal Foundation) Morris Animal Foundation-funded researchers have developed a new treatment for dogs with a rare, but life-threatening, arrhythmia caused by atrioventricular accessory pathways (APs). The minimally invasive technique, which uses radiofrequencies, is modified from a human cardiology procedure and has a more than 95 percent success rate in treating dogs with this type of arrhythmia. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - December 10, 2018 Category: International Medicine & Public Health Source Type: news

FFR for CABG; Botox Arrhythmia Prevention; Med Device Investigations
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 3, 2018 Category: Urology & Nephrology Source Type: news

J & J ’ s Biosense Webster launches Heliostar multi-electrode ablation cath trial
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster said this week that it enrolled and treated the first patient in its Stellar U.S. investigational device exemption study. The 640-patient trial is designed to assess the safety and efficacy of the Heliostar multi-electrode radiofrequency balloon ablation catheter as a treatment for drug refractory recurrent paroxysmal atrial fibrillation. The Heliostar device features 10 electrodes and is designed to allow electrophysiologists to achieve pulmonary vein isolation with a single application of RF energy, according to Biosense Webster. Cardiac electrophysiologists Drs. ...
Source: Mass Device - November 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Catheters Clinical Trials Featured Wall Street Beat Biosense Webster johnsonandjohnson Source Type: news

J & amp;J Subsidiary Launches IDE Study for AF
A new U.S. study aims to evaluate a radiofrequency (RF) balloon ablation catheter for the treatment of symptomatic drug refractory recurrent paroxysmal (intermittent) atrial fibrillation. Biosense Webster, a subsidiary of Johnson & Johnson, said the investigational device exemption study will enroll up to 640 patients at as many as 40 clinical sites worldwide. The STELLAR study will evaluate the company's Heliostar RF balloon ablation catheter. "This new balloon catheter is unique because it conforms to any pulmonary vein anatomy and allows me to control electrodes individually ...
Source: MDDI - November 29, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

BioSig inks Pure EP first-in-human study deal with Texas Cardiac Arrhythmia Institute
BioSig Technologies (OTCQB: BSGM) said today that it inked a deal with Austin’s Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to launch first-in-human studies using its Pure EP system. The Santa Monica, Calif.-based company’s Pure EP system is designed for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology procedures. The device is intended to reduce noise and artifacts to produce high-fidelity cardiac signals, which the company claims...
Source: Mass Device - November 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Clinical Trials BioSig Technologies Source Type: news

Arrhythmia after an Energy Drink: SVT?
ECG Challenge: A 32-year-old woman is brought by ambulance to the ED. She is having palpitations after consuming 2 energy drinks. What's your ECG read? (Source: ConsultantLive)
Source: ConsultantLive - November 26, 2018 Category: Internal Medicine Authors: Brady Pregerson, MD Tags: Cardiovascular Diseases Source Type: news

Abbott launches FlexAbility cath ventricular tachycardia ablation trial
Abbott (NYSE:ABT) said yesterday that it launched a study aiming to evaluate ablation treatments for patients with ventricular tachycardia, touting it as the first such trial of its kind. In the trial, dubbed the Less-VT study, investigators will explore the safety and effectiveness of ablation with the Chicago-area medtech giant’s FlexAbility ablation catheter in treating monomorphic ventricular tachycardia in patients who are unresponsive to drug therapy. “For some patients with sustained monomorphic ventricular tachycardia, drug therapy is an ineffective treatment option. We want to build a body of clin...
Source: Mass Device - November 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Featured Abbott Source Type: news

Abbott Initiates Study to Evaluate Ablation as a Frontline Treatment for Patient's Suffering from a Common but Complex Cardiac Arrhythmia
LESS-VT Study is the first U.S. clinical trial to evaluate the safety and effectiveness of ablation treatment for patients with monomorphic ventricular tachycardia, a common heart rhythm disorder (Source: Abbott.com)
Source: Abbott.com - November 20, 2018 Category: Pharmaceuticals Source Type: news

What is sick sinus syndrome?
Sick sinus syndrome ? also known as sinus node disease or sinus node dysfunction ? is a group of heart rhythm problems (arrhythmias) in which the heart's natural pacemaker (sinus node) doesn't work properly. The sinus node is an area of specialized cells in the upper right chamber of the heart that controls the rhythm [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 20, 2018 Category: Databases & Libraries Source Type: news

The association between unexplained falls and cardiac arrhythmias: a scoping literature review - Wiseman T, Betihavas V.
BACKGROUND: Falls in older adults are common. Age is a risk factor for falls and with an ageing population, presentation to the emergency department (ED) resulting from falls is rising. Reasons for falls in older adults are numerous and include cardiac arr... (Source: SafetyLit)
Source: SafetyLit - November 16, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EP ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EP
A small study suggests that ventricular arrhythmia may be treated without the need for catheters and anesthesia. John Mandrola, MD, is impressed with the findings and the investigators'lack of hyperbole.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Cardiva touts results from pivotal Vascade MVP vascular closure device trial
Cardiva Medical today released results from the pivotal study of its Vascade MVP vascular closure device intended for multi-access venous closure following electrophysiology procedures, touting that the trial met its primary and secondary endpoints. The results from the AMBULATE trial were presented today at the American Heart Association’s annual Scientific Sessions by Texas Cardiac Arrhythmia Institute exec medical director Dr. Andrea Natale. The Vascade system is composed of a thrombogenic bioabsorbable collagen patch and a collapsible mesh disc, the Santa Clara, Calif.-based company said. The device fun...
Source: Mass Device - November 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Cardiva Medical Inc. Source Type: news

Cardiva Medical Has Strong Showing at AHA
Cardiva Medical’s vascular closure system has met its clinical endpoints in the AMBULATE randomized pivotal trial. The Santa Clara, CA-based company’s VASCADE MVP, a vascular closure system designed specifically for multi-access venous closure following electrophysiology procedures such as arrhythmia ablation was evaluated in the study. Results from the trial were presented at American Heart Association 2018 Scientific Sessions, held in Chicago. AMBULATE enrolled 204 patients who underwent arrhythmia ablation procedures by 28 physicians at 13 sites across the US. The treatment group had ...
Source: MDDI - November 9, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Medical News Today: How does a doctor diagnose atrial fibrillation?
Atrial fibrillation creates an irregular heart rhythm called arrhythmia. A doctor can use physical examination and machine testing to diagnose and treat this common heart disorder. Read on to learn more. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 9, 2018 Category: Consumer Health News Tags: Heart Disease Source Type: news

Some MI risk factors more hazardous to women than to men
Diabetes, smoking and hypertension more strongly associated with MI in women than in men Related items fromOnMedica Wait and hip measurement better indicator of heart attack risk than obesity Death rate higher in women after discharge for heart arrhythmias Women more likely to survive heart attack if treated by female doctor Raised risk of MI and mortality when starting sulfonylurea (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 8, 2018 Category: UK Health Source Type: news

CardioMech taps medtech vet Nehm for CEO | Personnel Moves, November 5, 2018
 CardioMech taps medtech veteran Nehm for CEO Swedish mitral valve repair company CardioMech said today that it named medical device industry veteran Richard Nehm as president & CEO effective immediately. Nehm’s resume includes stints at Boston Scientific (NYSE:BSX), Abbott (NYSE:ABT) acquisition Tendyne and ATS Medical (acquired by Medtronic (NYSE:MDT)). CardioMech also named Spinal Stabilization Technologies president & CEO Mark Novotny as chairman. “There are more than 400,000 patients around the world that suffer from a leaky mitral valve due to prolapse or flail that are at a high-risk fo...
Source: Mass Device - November 5, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Business/Financial News Cantel Medical Corp. CardioMech Eos Imaging intersectent Medibio micronsolutions Personnel Moves Restoration Robotics Inc. Stereotaxis SurModics Inc. Vascular Insights Source Type: news

Preventing sudden cardiac death with genome editing
(Baylor College of Medicine) Gene editing successfully prevented sudden cardiac death in a mouse model of inherited cardiac arrhythmia disorder. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 30, 2018 Category: Biology Source Type: news

FDA approves Abbott ’ s HeartMate 3 as a destination therapy
Abbott (NYSE:ABT) said today it won FDA approval for its HeartMate 3 left ventricular assist device, now approved as a destination therapy for patients with advanced heart failure. With the approval, the Chicago-based company said that the device can now be used in patients not eligible for a transplant as a life-long implant. “We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes. The unique design of the HeartMate 3 LVAD—with its Full MagLev technology—takes an established innovation and improves upon it in meaningful ways to help people with...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

Study Highlights Surgery Benefits of P/D over EPP for Mesothelioma
This study focused on 30-day mortality and postoperative complications. It included a meta-analysis of 39 previous studies from 1990 to 2017, along with the New York Statewide Planning and Research Cooperative System database from 1995 to 2012. Study results included: 30 Day Mortality: EPP 5 percent; P/D 2 percent Postoperative Complications: EPP 46 percent; P/D 24 percent Postoperative Arrhythmias: EPP 20 percent; P/D 5 percent. Although there is no cure for pleural mesothelioma, aggressive surgery — with either the P/D or EPP — has been proven to extend survival times. According to a recent study pub...
Source: Asbestos and Mesothelioma News - October 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

With Loop Recorder, Many Could Skip ICD for Inherited Arrhythmia
(MedPage Today) -- Devices get patients the right event adjudication, per single-center analysis (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - October 15, 2018 Category: Surgery Source Type: news

Respiratory sinus arrhythmia mediates links between borderline personality disorder symptoms and both aggressive and violent behavior - Thomson ND, Beauchaine TP.
Although emotion dysregulation (ED) is a core symptom of borderline personality disorder (BPD), tests of associations between ED and aggression and violence-which are common to BPD-are sparse. The authors evaluated mediating effects of an autonomic vulnera... (Source: SafetyLit)
Source: SafetyLit - October 15, 2018 Category: International Medicine & Public Health Tags: Violence and Weapons Issues Source Type: news

Cardialen Closes $17M Series B
Cardialen closed a $17 million Series B investment led by RiverVest Venture Partners, along with Qiming Venture Partners, HBM Healthcare Investments and Cultivation Capital. The Minneapolis-based company said it is developing the Cardialen unpinning termination (UPT) therapy, which delivers a sequence of low-energy electrical pulses designed to restore abnormally rapid heart rates to a normal rhythm. This low-energy therapy is intended to mitigate the negative effects of current high-energy defibrillators by delivering a much more tolerable, less debilitating treatment for patients with heart arrhythmias. â€...
Source: MDDI - October 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

NYT Report: Apple Watch ‘ should not be considered a medical device ’
The new electrocardiogram-equipped Apple (NSDQ:AAPL) Watch should not be considered a medical device, according to a new report from the New York Times. The article, written by Indiana University School of Medicine pediatrics professor Aaron Carroll, calls into question the downsides of the newly released device and the potential for both false positives and false negatives. Carroll acknowledged the possible positives of the device, including the ability for physicians to monitor patients from a distance and diagnosing heart problems in individuals that would possibly go undetected, but said that “just because s...
Source: Mass Device - October 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Diagnostics mHealth (Mobile Health) Apple Source Type: news

Pins and needles: How acupuncture can help soothe an irregular heartbeat
(Natural News) Cardiac arrhythmia describes an irregular heartbeat caused by an interruption of electrical impulses in heart function. This group of conditions can be further broken down into bradycardia (slow heartbeat), tachycardia (fast heartbeat), flutter or fibrillation (irregular heartbeat), or premature contraction (early heartbeat). While most types of heart arrhythmia are relatively harmless (caused by... (Source: NaturalNews.com)
Source: NaturalNews.com - October 6, 2018 Category: Consumer Health News Source Type: news

Judge pares claims in Bard IVC bellwether
A federal judge in Arizona yesterday pared some claims in the third bellwether case involving inferior vena cava filters made by Becton Dickinson (NYSE:BDX) subsidiary C.R. Bard, as the trial entered its 11th day. It’s the fourth bellwether in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through the body’s largest vein into the heart and lungs. In the first case to go to trial, a federal jury in Phoenix found for plaintiff Sherr-Una Booker, awarding $3.6 million in damages. Bard prevailed in the second bellwether trial, with the jury findin...
Source: Mass Device - October 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Legal News Product Liability Vascular bectondickinson crbard Source Type: news

Just Where Does Apple ’s New ECG Fit into the Market?
The inclusion of two heart monitoring apps with the upcoming Apple Watch 4 is causing quite a stir in the wearable device market. Last week, Cupertino, CA-based Apple revealed it received nods from FDA for its wearable watch to include an ECG app, that can classify whether there are signs of atrial fibrillation (AFib), and another app that analyzes pulse rates for irregular rhythms. Earlier this year, MD+DI reported that Apple was working on an FDA submission. The agency has gone on record and said Apple’s solution isn’t designed to replace "traditional metho...
Source: MDDI - September 14, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

New Apple Watch OK'd for Arrhythmia Detection
(MedPage Today) -- Single-lead electrocardiogram built into latest version cleared by FDA (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 12, 2018 Category: American Health Source Type: news

InfoBionic drums up $50m for MoMe Kardia remote heart monitor
InfoBionic said today that it raised another $50 million for its wireless remote cardiac monitor. Boston-based InfoBionic said Eagle Investments, Excel Venture Management, Safeguard Scientifics, Blue Cross Blue Shield of Massachusetts subsidiary Zaffre Investments and Blue Cross and Blue Shield of Kansas all participated in the round. The company sells the MoMe Kardia device, a remote, wireless outpatient system for monitoring & diagnosis of cardiac arrhythmias. It won 510(k) clearance from the FDA in 2015. Last month, InfoBionic inked a deal giving exclusive U.S. distribution rights for the MoMe Kardia syste...
Source: Mass Device - September 11, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Funding Roundup Patient Monitoring Wall Street Beat InfoBionic Source Type: news

Biotronik Enters into Distribution Agreement with InfoBionics
Biotronik has become the exclusive US distributor for InfoBionic's MoMe Kardia external cardiac diagnostic monitor. The device benefits patients suspected of experiencing cardiac arrhythmias. “When we’re looking at partners - we’re asking ourselves - are these partners able to do the three main things that are important to us,” Rupa Basu, Senior Vice President of Marketing, Corporate Accounts and Strategy, at Biotronik, told MD+DI. “The first thing is, is it going to improve the patient’s expe...
Source: MDDI - September 7, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news

Understanding the victimization-aggression link in childhood: the roles of sympathy and resting respiratory sinus arrhythmia - Colasante T, Peplak J, Sette S, Malti T.
With a sample of 4- and 8-year-olds (N = 131), we tested the extent to which more frequent experiences of victimization were associated with heightened aggression towards others, and how sympathetic concern and resting respiratory sinus arrhythmia (RSA) fa... (Source: SafetyLit)
Source: SafetyLit - September 7, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Chest Pain Drug Ranolazine Falls Short in Preventing First Episode of Ventricular Arrhythmia or Death
A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the chest pain drug ranolazine was safe but didn ’t decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - September 5, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Texas medical-device company closes Bucks County office, eliminates 62 jobs
The company that shut down its Langhorne office markets a mobile arrhythmia diagnostic device. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 4, 2018 Category: Biotechnology Authors: John George Source Type: news

Medtronic touts 1-year Arctic Front cryoballoon study data
Medtronic (NYSE:MDT) today released results from the Cryo4Persistent AF clinical trial of its Arctic Front Advance cryoablation system, touting reductions in the symptoms of abnormal heart rhythms and a low rate of re-interventions and repeat ablations. The Fridley, Minn.-based company said it presented results from the trial at the 2018 European Society of Cardiology Congress in Munich this week. “These findings highlight the advantage of cryoballoon ablation in patients with persistent AF, demonstrating that patients have fewer symptoms after treatment and a significant improvement in their quality of life. Pa...
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Medtronic Source Type: news

Biotronik to distribute InfoBionic monitor in U.S.
Biotronik has landed exclusive U.S. distributorship for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor. MoMe Kardia was designed to increase early detection and diagnosis of cardiac arrhythmias by providing physicians with the ability to access near real-time electrocardiographic data. Monitoring can also uncover patients at higher risk of sudden cardiac death. Get the full story on our sister site, Medical Design & Outsourcing. The post Biotronik to distribute InfoBionic monitor in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiac Assist Devices Distribution Biotronik InfoBionic Source Type: news

Chest pain drug falls short in preventing first episode of ventricular arrhythmia or death
(University of Rochester Medical Center) A trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine (used to treat chest pain; brand name Ranexa ® ) was safe but didn't decrease the likelihood of the first occurrence of ventricular arrhythmias or death in this high-risk population. The drug did lower the risk for recurrent ventricular tachycardia by 30 percent, suggesting it could be a treatment option for this very sick population for which there are limited therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: What are the effects of bulimia on the body?
Bulimia is an eating disorder that involves bingeing and purging. It can affect a person ’s physical, mental, and emotional health. The side effects, which include tooth decay, digestive issues, and arrhythmia, may become severe without treatment. Here, learn about the signs of bulimia and its effects on the body. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 23, 2018 Category: Consumer Health News Tags: Eating Disorders Source Type: news

Arrhythmias and Cognitive Function Arrhythmias and Cognitive Function
What impact do arrhythmias have on cognitive impairment and decline? This brief highlights the major conclusions of a recent expert consensus statement.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 21, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Afib and Aflutter: Should We Be “Lumpers” or “Splitters”?
Results of a new study may prompt you to rethink how you approach anticoagulation for these 2 arrhythmias. Are they 1 entity, or 2? (Source: ConsultantLive)
Source: ConsultantLive - August 13, 2018 Category: Internal Medicine Authors: Payal Kohli, MD Tags: Atrial Fibrillation Source Type: news

Bankers in their twenties suffering more heart attacks, doctors warn
These unlikely patients regularly present themselves with two types of heart conditions: cardiac arrhythmia and myocarditis. (Source: the Mail online | Health)
Source: the Mail online | Health - August 6, 2018 Category: Consumer Health News Source Type: news

Have We Reached the Point of Primary Prevention for AF? Have We Reached the Point of Primary Prevention for AF?
Should we offer primary prevention therapy for patients at risk of atrial fibrillation, even before the arrhythmia has occurred? What are the risks, and which patients would benefit?Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Heart arrhythmia symptoms: Speak to your doctor if you feel this in your chest
HEART arrhythmia symptoms depend on what variation of the condition you have, but there are five common signs associated with all abnormal heart rhythms. One is a particular feeling in your chest. (Source: Daily Express - Health)
Source: Daily Express - Health - July 30, 2018 Category: Consumer Health News Source Type: news

The future of Abbott ’ s electrophysiology business
At DeviceTalks Minnesota 2018, medtech veteran Michael Pederson provided an inside look at the Abbott-St. Jude Medical merger and what’s ahead for Abbott’s cardiovascular technologies. Pederson tracked his career from a formative stint at HP to his current role as SVP of cardiac arrhythmias and heart failure at Abbott (NYSE:ABT). Check out his keynote address with DeviceTalks founder Brian Johnson. To learn more from the brightest minds in medtech, don’t miss DeviceTalks Boston on Oct. 8-10 The post The future of Abbott’s electrophysiology business appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Cardiovascular DeviceTalks Q&A Wall Street Beat Abbott DeviceTalks Boston DeviceTalks Minnesota Source Type: news

7 medtech stories we missed this week: July 27, 2018
[Image from unsplash.com]From the FDA clearing LifeSignal’s wireless ECG to Zavation receiving FDA clearance for its expandable corpectomy cage, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears LifeSignal’s wireless ECG LifeSignals announced in a July 26 press release that it has received FDA clearance for its wireless LP1100 Life Signal Patch. The patch is designed to be used in wearables and healthcare monitoring devices. The clearance allows the company to use the Life Signal Processor to develop ECG and other vital sign monitoring wearables ...
Source: Mass Device - July 27, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Diagnostics Food & Drug Administration (FDA) Hospital Care Imaging Patient Monitoring Prosthetics Regulatory/Compliance DoseOptics FBC Device Flashback Technologies Health.io LifeSignal Medi-Lynx Cardiac Monitoring MedTe Source Type: news

This engineered heart ventricle helps with studying arrhythmia and cardiomyopathy
[Luke MacQueen and Michael Rosnach/Harvard University]While engineered heart tissues can replicate muscle contraction and electrical activity in a dish, many aspects of heart disease can only adequately be captured in 3D. In a report published online yesterday by Nature Biomedical Engineering, researchers describe a scale model of a heart ventricle, built to replicate the chamber’s architecture, physiology and contractions. Cardiac researchers at Boston Children’s Hospital think it could help them find treatments for congenital heart diseases. Building a 3D engineered heart ventricle Collaborators from the Harv...
Source: Mass Device - July 26, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog Vector Blog Source Type: news

Deaths linked to heat set to rise sharply
MPs warn heat-related deaths could treble by 2050 Related items fromOnMedica Cold snap has immediate effect on emergency admissions Particulate levels linked to arrhythmias and embolisms Poor patients more likely to die after heart surgery than rich Active elderly live independently and avoid social care Volume of exercise in older men more beneficial than duration (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 26, 2018 Category: UK Health Source Type: news

A 3D model of a human heart ventricle
(Harvard John A. Paulson School of Engineering and Applied Sciences) Harvard University researchers have bioengineered a three-dimensional model of a human left heart ventricle that could be used to study diseases, test drugs and develop patient-specific treatments for heart conditions such as arrhythmia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 23, 2018 Category: International Medicine & Public Health Source Type: news

A 3-D model of a human heart ventricle
(Harvard John A. Paulson School of Engineering and Applied Sciences) Harvard University researchers have bioengineered a three-dimensional model of a human left heart ventricle that could be used to study diseases, test drugs and develop patient-specific treatments for heart conditions such as arrhythmia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 23, 2018 Category: Biology Source Type: news

Google executive Heidi Dohse on becoming a heart patient
For more than 30 years, Google (NSDQ:GOOG) executive Heidi Dohse has been fully dependent on pacemakers to help power her heart. But that hasn’t stopped her from becoming a competitive cyclist, competing in events around the world. At DeviceTalks Minnesota, Dohse spoke with Randall Shiestl, VP of R&D at Boston Scientific‘s (NYSE:BSX) global technology unit, about her journey through the healthcare system and into the world of medical technology after she was diagnosed with a rare arrhythmia in 1983. Now on her seventh pacemaker, Dohse shared her story of learning to trust the medical devices that keep ...
Source: Mass Device - July 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiac Implants Boston Scientific Google Inc. Source Type: news

New Cochrane health evidence challenges belief that omega 3 supplements reduce risk of heart disease, stroke or death
New evidence published today shows there is little or no effect of omega 3 supplements on our risk of experiencing heart disease, stroke or death.Omega 3 is a type of fat. Small amounts of omega 3 fats are essential for good health, and they can be found in the food that we eat. The main types of omega 3 fatty acids are; alpha ­linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).  ALA is normally found in fats from plant foods, such as nuts and seeds (walnuts and rapeseed are rich sources). EPA and DHA, collectively called long chain omega 3 fats, are naturally found in fatty fish, su...
Source: Cochrane News and Events - July 16, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

NinePoint Medical lifts Namati to the corner office | Personnel Moves – July 10, 2018
NinePoint Medical said earlier this month that it appointed Eman Namati as its new president and chief executive officer, succeeding Christopher von Jako who will remain on the company’s board of directors. Namati joined NinePoint Medical at its inception in 2010 as a technical co-founder, and operated as R&D VP for the past four years, the Bedford, Mass.-based company said. “With the recent strategic partnership NinePoint entered into with Merit Medical, along with Eman’s long history with the technology, business acumen, and strong leadership, this was a natural choice for the Board and a great next...
Source: Mass Device - July 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Alfred Mann Foundation Bonesupport Cutera Inc. Endologix GE Healthcare iRhythm Technologies Inc. Merit Medical Systems Inc. NinePoint Medical Inc. personnel-moves RTI Surgical SeaSpine second-sight-medical Source Type: news